Jul 1, 2013 · Nonalcoholic fatty liver disease is characterized by excessive fat accumulation in the liver (hepatic steatosis). Nonalcoholic steatohepatitis is characterized by steatosis, liver cell...

Nonalcoholic Fatty Liver Disease (NAFLD) is initially suspected when blood tests show elevated levels of liver enzymes and tests for hepatitis B, C, and autoimmune liver disease are negative in persons who do not drink alcohol or drink in no more than moderate amounts.

The term NAFLD actually refers to a group of related liver conditions, including simple fatty liver (i.e. steatosis), non-alcoholic steatohepatitis (steatosis with liver damage/NASH), fatty liver with liver fibrosis (i.e. liver scarring), or fatty liver with advanced liver fibrosis/cirrhosis.

This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. “Guidance” document is different from a “Guideline.”

Here are the key recommendations for blood testing and referral developed by AACE and cosponsored by AASLD.1. The FIB-4 index is the preferred noninvasive initial test to assess the risk of NAFLD with liver fibrosis. (Repeat testing every 2 …

NAFLD is a spectrum of disease, defined as a population in which ≥5% of hepatocytes display macrovascular steatosis, in the absence of alternative causes in individuals who drink little/no alcohol.

Algorithm for the evaluation of patients at risk for or with established NAFLD across practice settings. Patients with steatosis noted on imaging or for whom there is a clinical suspicion of NAFLD, such as those with metabolic risk factors or unexplained elevation in liver chemistries, should undergo further evaluation.

In this review, we will critically analyse both the converging and diverging points in the current clinical guidelines of NAFLD, with a particular focus on the diagnostic and therapeutic aspects.

This guideline provides evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other stakeholders.

Screening and Treatment Algorithm for Nonalcoholic Fatty Liver Disease in Primary Care Clinics. Although the gold standard for diagnosing NAFLD and NASH with and without fibrosis is liver biopsy, this method is often impractical, expensive, and not without risk. Figure 1 illustrates an algorithm to be used by PCPs to screen for NAFLD.